We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

FLT3

FMS-like tyrosine kinase 3 (FLT3) inhibitors act on a receptor tyrosine kinase of early blood cell progenitors. FLT3 and its ligand support the survival and expansion of hematopoietic stem and progenitor cells. In 1996 internal tandem duplications (ITDs) of the FLT3 juxtamembrane region were found in acute myeloid leukemia (AML). These mutations, like kinase domain point mutations such as D835Y, keep the receptor constitutively active. Quizartinib and gilteritinib are widely used FLT3 inhibitors in AML cell models, and gilteritinib also inhibits the receptor tyrosine kinase anexelekto (AXL). Crenolanib also targets platelet-derived growth factor receptors (PDGFRs), and pacritinib inhibits both FLT3 and Janus kinase 2 (JAK2).

1 Item

  • BDT001
    Cat. No.
    A33706
    CAS No.
    823837-22-5

    BDT001

    BDT001 is a selective FLT3 receptor antagonist that inhibits the signaling pathways associated with FLT3 activation. This compound demonstrates significant potential in research applications focused on pain disorders, cancer, and autoimmune diseases by modulating the activity of FLT3, a receptor implicated in cellular proliferation and survival. BDT001 serves as a valuable tool for investigating therapeutic strategies targeting FLT3-related pathologies.

    View Details

    Out of stock

    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...